← Leaderboards
Poulikos I Poulikakos
Icahn School Of Medicine At Mount Sinai
$5,543,909
Attributed
$5,543,909
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,543,909 · 3
By mechanism
R01$5,543,909 · 3
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Javier Gonzãlez-Maeso$8,339,334
- Marta Filizola$11,220,258
- Bruce D Gelb$39,999,464
- Lahouaria Hadri$8,134,686
- Martin Lohse$662,613
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsTargeted TreatmentSmall Molecule InhibitorTumorResponseResistanceSignal TransductionDesignExperimental StudyMutantRegulationOncogenicBiochemicalRas/RafCellsNormal CellBraf GeneComplexEffectivenessEffective TherapyInsightIn VivoMutationMeks
Grant awards (13)
Mechanisms determining tumor-selective potency of RAS pathway inhibitors$689,006
R01 · FY2025 · CA · contact PI
Mechanisms determining tumor-selective potency of RAS pathway inhibitors$723,506
R01 · FY2024 · CA · contact PI
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING$396,453
R01 · FY2024 · CA · contact PI
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING$408,974
R01 · FY2023 · CA · contact PI
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING$408,974
R01 · FY2022 · CA · contact PI
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING$417,319
R01 · FY2021 · CA · contact PI
Mechanism-based strategies to target oncogenic BRAF signaling$387,886
R01 · FY2021 · CA · contact PI
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING$404,489
R01 · FY2020 · CA · contact PI
Mechanism-based strategies to target oncogenic BRAF signaling$387,886
R01 · FY2020 · CA · contact PI
Mechanism-based strategies to target oncogenic BRAF signaling$376,248
R01 · FY2019 · CA · contact PI
Mechanism-based strategies to target oncogenic BRAF signaling$135,600
R01 · FY2019 · CA · contact PI
Mechanism-based strategies to target oncogenic BRAF signaling$393,164
R01 · FY2018 · CA · contact PI
Mechanism-based strategies to target oncogenic BRAF signaling$414,404
R01 · FY2017 · CA · contact PI